Cidara Therapeutics, Inc.
CDTX
$22.50
$0.140.63%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -- | -94.07% | -84.36% | -73.45% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -- | -94.07% | -84.36% | -73.45% |
| Cost of Revenue | 485.19% | 19.67% | -23.10% | -39.04% | -63.50% |
| Gross Profit | -792.16% | -963.22% | -78.16% | -41.72% | 54.57% |
| SG&A Expenses | 112.01% | 50.50% | 49.20% | -1.56% | -37.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 372.92% | 27.10% | -3.67% | -28.80% | -58.23% |
| Operating Income | -522.71% | -289.30% | -64.51% | -19.59% | 48.97% |
| Income Before Tax | -540.68% | -302.98% | -1,438.12% | -18.32% | 51.60% |
| Income Tax Expenses | -- | -- | -- | -- | -97.43% |
| Earnings from Continuing Operations | -540.13% | -306.36% | -1,428.14% | -18.32% | 52.33% |
| Earnings from Discontinued Operations | -98.75% | 91.48% | 140.23% | -121.65% | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1,527.98% | -75.52% | -569.47% | -442.71% | 81.28% |
| EBIT | -522.71% | -289.30% | -64.51% | -19.59% | 48.97% |
| EBITDA | -524.62% | -290.31% | -64.57% | -19.62% | 49.08% |
| EPS Basic | -657.34% | -21.35% | -560.98% | -397.19% | 85.13% |
| Normalized Basic EPS | -198.05% | -178.60% | -50.34% | -2.61% | 61.56% |
| EPS Diluted | -655.13% | -21.20% | -560.82% | -397.19% | 85.08% |
| Normalized Diluted EPS | -198.05% | -178.60% | -50.34% | -2.61% | 61.56% |
| Average Basic Shares Outstanding | 114.97% | 44.65% | 1.29% | 15.31% | 25.88% |
| Average Diluted Shares Outstanding | 114.97% | 44.65% | 1.29% | 15.31% | 25.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
